BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20551943)

  • 1. Therapy with azanucleosides for myelodysplastic syndromes.
    Quintás-Cardama A; Santos FP; Garcia-Manero G
    Nat Rev Clin Oncol; 2010 Aug; 7(8):433-44. PubMed ID: 20551943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
    Duong VH; Lin K; Reljic T; Kumar A; Al Ali NH; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):711-5. PubMed ID: 24054159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
    Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
    Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demethylating agents in myeloid malignancies.
    Garcia-Manero G
    Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of decitabine in the treatment of myelodysplastic syndromes.
    Atallah E; Kantarjian H; Garcia-Manero G
    Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
    DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
    Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.